PMID- 10209962
OWN - NLM
STAT- MEDLINE
DCOM- 19990429
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 81
IP  - 3
DP  - 1999 May 5
TI  - Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted
      and tumor-specific cytotoxic T lymphocytes.
PG  - 459-66
AB  - We have described the SART-1 gene-encoding peptides recognized by
      HLA-A2601-restricted and tumor-specific cytotoxic T lymphocytes (CTLs). We now
      have investigated whether SART-1 encodes peptides capable of inducing the
      HLA-A24-restricted CTLs. Among the 18 different peptides with HLA-A24-binding
      motifs, the SART-1(690-698) peptide (EYRGFTQDF) was most strongly recognized by
      the HLA-A24-restricted and tumor-specific CTLs established from an esophageal
      cancer patient. After a third stimulation in vitro, this peptide induced
      HLA-A24-restricted CTLs recognizing the SART-1(259)+ tumor cells in PBMCs of all 
      HLA-A24 homozygous and the majority of HLA-A24 heterozygous cancer patients and
      healthy donors tested. A similar activity, induction of CTLs from PBMCs, was
      observed in the Saccharomyces cerevisiae-derived nonapeptide (EYRGFTPMF) that
      shares 7 amino acids with the SART-1(690-698) peptide. The SART-1(690-698)
      peptide-induced CTL activity was significantly higher in PBMCs of HLA-A24
      homozygotes than in HLA-A24 heterozygotes. The CTL precursor frequency in PBMCs
      after a third stimulation in vitro with the SART-1(690-698) peptide was high
      (>1/200) in both cancer patients and healthy donors. The SART-1(690-698) peptide 
      could thus be useful for specific immunotherapy of HLA-A24+ cancer patients.
FAU - Kikuchi, M
AU  - Kikuchi M
AD  - Cancer Vaccine Development Division of Kurume University Research Center for
      Innovative Cancer Therapy, Kurume University School of Medicine, Japan.
FAU - Nakao, M
AU  - Nakao M
FAU - Inoue, Y
AU  - Inoue Y
FAU - Matsunaga, K
AU  - Matsunaga K
FAU - Shichijo, S
AU  - Shichijo S
FAU - Yamana, H
AU  - Yamana H
FAU - Itoh, K
AU  - Itoh K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Ribonucleoproteins, Small Nuclear)
RN  - 0 (SART1 protein, human)
SB  - IM
MH  - *Antigens, Neoplasm
MH  - Cell Line
MH  - Cytotoxicity, Immunologic
MH  - HLA-A Antigens/*immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Neoplasm Proteins/*immunology
MH  - Neoplasms/*immunology/therapy
MH  - Peptide Fragments/*immunology
MH  - *Ribonucleoproteins, Small Nuclear
MH  - Saccharomyces/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 1999/04/21 02:03
MHDA- 2000/06/20 09:00
CRDT- 1999/04/21 02:03
PHST- 1999/04/21 02:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/04/21 02:03 [entrez]
AID - 10.1002/(SICI)1097-0215(19990505)81:3<459::AID-IJC21>3.0.CO;2-6 [pii]
AID - 10.1002/(sici)1097-0215(19990505)81:3<459::aid-ijc21>3.0.co;2-6 [doi]
PST - ppublish
SO  - Int J Cancer. 1999 May 5;81(3):459-66. doi:
      10.1002/(sici)1097-0215(19990505)81:3<459::aid-ijc21>3.0.co;2-6.